Updates on Clinical Trial Enrollment, Product Development Updates, Clinical Collaboration, and Preliminary Sales Report - Research Report on Raptor, Synageva, XenoPort, Portola, and Zogenix

NEW YORK, January 16, 2014 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Raptor Pharmaceutical Corp. (NASDAQ: RPTP), Synageva BioPharma Corporation (NASDAQ: GEVA), XenoPort, Inc. (NASDAQ: XNPT), Portola Pharmaceuticals, Inc. (NASDAQ: PTLA), and Zogenix, Inc. (NASDAQ: ZGNX). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Raptor Pharmaceutical Corp. Research Report

On January 13, 2014, Raptor Pharmaceutical Corp. (Raptor) announced that its Phase 2b clinical trial, evaluating the safety and potential efficacy of RP103 delayed-release cysteamine bitartrate as a prospective treatment of non-alcoholic fatty liver disease (NAFLD) in children, has met its enrollment target. The Company informed that the trial, called Cysteamine Bitartrate Delayed-Release for the Treatment of Non-Alcoholic Fatty Liver Disease in Children (CyNCh), has enrolled 160 pediatric participants at 10 U.S. centers in the NIDDK-sponsored NASH Clinical Research Network. Raptor stated that it expects full results from the Phase 2b CyNCh trial in H1 2015. The Full Research Report on Raptor Pharmaceutical Corp. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/a001_RPTP

--

Synageva BioPharma Corporation Research Report

On January 6, 2014, Synageva BioPharma Corporation (Synageva) announced that ARISE (Acid Lipase Replacement Investigating Safety and Efficacy), a global Phase 3 trial with sebelipase alfa in children and adults with lysosomal acid lipase deficiency (LAL Deficiency), has completed total enrollment. The Company informed that the enrollment exceeded the original target of 50 patients with 66 randomized as of December 31, 2013. Synageva informed that it expects to report top-line results from the ARISE trial in H2 2014. In addition, the Company announced that it has met the enrollment target in the Phase 2/3 trial in infants with LAL Deficiency, and the preliminary results for the same will be presented at the 10^th Annual Lysosomal Disease Network (LDN) WORLD Symposium on February 11-13, 2014, in San Diego, California. The Full Research Report on Synageva BioPharma Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/8624_GEVA

--

XenoPort, Inc. Research Report

On January 12, 2014, XenoPort, Inc. (XenoPort) reported an update on the development of XP23829, including feedback from the U.S. Food and Drug Administration (FDA) on the potential development plans, and the Company's progress on commercializing HORIZANT (gabapentin enacarbil) Extended-Release Tablets. The Company stated that based on the feedback from the FDA Division of Neurology Products regarding potential development plans for XP23829 as a potential treatment for patients with relapsing forms of multiple sclerosis (MS), XenoPort believes that the FDA would allow the Company to initiate potential Phase 3 clinical development using XP23829 doses that produce monomethyl fumarate (MMF) exposure similar to that produced by the approved dose of TECFIDERA (dimethyl fumarate). XenoPort added that in 2014, it intends to submit an Investigational New Drug (IND) application to the FDA Division of Dermatology for XP23829 as a potential treatment for moderate-to-severe plaque psoriasis. In addition, XenoPort reported its progress in the commercialization of HORIZANT, and stated that it has made substantial progress in enhancing the value of the HORIZANT business. "Based on our current operating plan, and assuming continued HORIZANT sales growth comparable to what we've experienced since we started commercializing HORIZANT, we believe that net sales of HORIZANT will exceed the sum of cost of product sold and selling, advertising and promotional expenses by the end of 2014, and that the HORIZANT business will reach break-even and turn profitable by the end of 2015." said Ronald W. Barrett, PhD, CEO of XenoPort. The Full Research Report on XenoPort, Inc. - including full detailed breakdown, analyst ratings and price targets - is  available to download free of charge at:  

http://www.analystscorner.com/r/full_research_report/a224_XNPT

--

Portola Pharmaceuticals, Inc. Research Report

On January 13, 2014, Portola Pharmaceuticals, Inc. (Portola) announced that it has entered into a second clinical collaboration agreement with Bristol-Myers Squibb Company (Bristol-Myers) and Pfizer Inc. (Pfizer) to study Portola's investigational Factor Xa inhibitor reversal agent, andexanet alfa, with the oral Factor Xa inhibitor Eliquis. The Company reported that the new clinical collaboration agreement will be in effect through Phase 3 studies with Eliquis and any potential US and EU regulatory approval of andexanet alfa. Portola informed that the Phase 3 studies are expected to start in H1 2014. "The FDA's recent designation of andexanet alfa as a breakthrough therapy recognizes the medical need for this antidote as well as its attributes, which distinguish it from general procoagulant approaches. Andexanet alfa is the only agent that has been shown to reverse the anticoagulation effect of Factor Xa inhibitors in humans," said William Lis, CEO of Portola. The Full Research Report on Portola Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/102f_PTLA

--

Zogenix, Inc. Research Report

On January 13, 2014, Zogenix, Inc. (Zogenix) announced preliminary unaudited gross product sales on sales of SUMAVEL DosePro for Q4 2013. The Company stated that it expects to report Q4 2013 gross product sales of c.$14 million on 141,780 units shipped, with unit volume growth of  c.2.2% QoQ. The Company added that Q4 2013 preliminary unaudited net product revenue on sales of SUMAVEL DosePro was c.$9 million, up c.30% QoQ. The Full Research Report on Zogenix, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/ef36_ZGNX

----

EDITOR NOTES:

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
5. For any urgent concerns or inquiries, please contact us at [email protected].
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

AnalystsCorner.com

SOURCE Analysts' Corner